EyePoint Pharmaceuticals (EYPT) Tops Q3 EPS by 2c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q3 EPS of ($0.54), $0.02 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $10.5 million versus the consensus estimate of $10.06 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• Lightwave Logic, Inc. (LWLG) Reports Q2 Loss of $0.04
• Global-e Online posts 44% GMV and 39% revenue growth in Q2 2026
• Oppenheimer Upgrades Intuitive Surgical (ISRG) to Outperform, 'Crowding Out Competitors Strategically Smart'